Halozyme Therapeutics, Inc. (HALO)
110.19
-0.57
(-0.51%)
USD |
NASDAQ |
Sep 04, 16:00
110.00
-0.19
(-0.17%)
Pre-Market: 09:10
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 12.57B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 50.12% |
| Valuation | |
| PE Ratio | 32.92 |
| PE Ratio (Forward) | |
| PS Ratio | 8.015 |
| Price to Book Value | 87.54 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 14.95 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 49.06% |
Profile
| Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA. |
| URL | http://www.halozyme.com |
| Investor Relations URL | https://ir.halozyme.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Growth |
| Next Earnings Release | Nov. 02, 2026 (est.) |
| Last Earnings Release | Aug. 06, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA. |
| URL | http://www.halozyme.com |
| Investor Relations URL | https://ir.halozyme.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Growth |
| Next Earnings Release | Nov. 02, 2026 (est.) |
| Last Earnings Release | Aug. 06, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |